Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody.
Meng X, Wang P, Xiong Y, Wu Y, Lin X, Lu S, Li R, Zhao B, Liu J, Zeng S, Zeng L, Wu Y, Lu Y, Zhang J, Liu D, Wang S, Lu H. Meng X, et al. Emerg Microbes Infect. 2021 Dec;10(1):1638-1648. doi: 10.1080/22221751.2021.1960900. Emerg Microbes Infect. 2021. PMID: 34346827 Free PMC article. Clinical Trial.
Population pharmacokinetics and model-informed precision dosing of lamivudine in Chinese HIV-infected patients with mild and moderate impaired renal function.
Wen H, Yin L, Wang J, Zhang L, Sun T, Xu F, Zhang M, Liu L, Zhang R, Liu X, Meng X, Xing Y, Lu H, Jiao Z, Zhang L. Wen H, et al. Among authors: meng x. Expert Rev Clin Pharmacol. 2022 May;15(5):647-655. doi: 10.1080/17512433.2022.2078306. Epub 2022 Jun 6. Expert Rev Clin Pharmacol. 2022. PMID: 35938476
13,967 results
You have reached the last available page of results. Please see the User Guide for more information.